Dr. Saeho Chong brings more than 25 years of senior management experience, including more than a decade of strategic development in the pharmaceutical industry. He most recently served as Vice President, Early Development at Alnylam Pharmaceuticals, where he had a significant track record of success in R&D.
Previously, he served in roles of increasing responsibility and leadership at Bristol-Myers Squibb and Millennium (Takeda Oncology). He also held a prior position in the U.S. Food and Drug Administration’s (FDA) Office of Clinical Pharmacology and was a professor of Pharmaceutical Sciences, College of Pharmacy at Seoul National University.
Dr. Seong H. Jang brings a deep expertise in clinical pharmacology, having held considerable positions of increasing responsibility at FDA for nearly 20 years. His experience includes leadership roles in the Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Center for Drug Evaluation and Research. He and his team contributed to the approval of an impressive portfolio of new drug products in multiple therapeutic areas, including transplant, special pathogen and anti-infectives.
He is widely recognized both internally and externally for his expertise and collaboration. Further, his contributions include serving as a cross disciplinary team leader in several NDA reviews and as an acting deputy division director for the Office of Study Integrity and Surveillance.
Jenny Gizzi joined Elevar Therapeutics as Chief of Staff to CEO and Chief People Officer in December 2021 and brings more than 20 years of human resources experience in the biopharmaceutical sector. As Chief of Staff, Jenny is responsible for overseeing Elevar’s human resources function, including talent acquisition and administration, leadership development, compensation and benefits, and diversity and inclusion.
Prior to joining Elevar, Jenny served as Vice President of Human Resources and Talent Acquisition at Arena Pharmaceuticals, Inc. where she was responsible for all people processes, workforce planning, recruitment, compliance, employee relations, and communications.
Paul has more than 30 years’ experience in the pharmaceutical industry, including leadership positions in multinational corporations and biotech companies. Paul most recently served as chief commercial officer at Beyond Spring, Inc. (NASDAQ: BYSI), a global, clinical-stage biopharmaceutical company. Previously, he served in roles of increasing responsibility and leadership at pharmaceutical company TAP/Takeda, including president and general manager at Takeda Canada.
Paul has launched more than 20 products during his career, including five that achieved more than $1 billion in sales. He also held early leadership positions in five start-ups and led business development for several large transitions and capital raises. He holds an MBA from the University of Kansas and a Bachelor of Science degree in business administration from Kansas State University.
Gordon Schooley is a global regulatory leader with more than 30 years of drug development experience. He joined Elevar after nine years as chief regulatory officer for BeyondSpring Pharmaceuticals Inc., a global, clinical-stage biopharmaceutical company that develops immuno-oncology cancer therapies.
Schooley has spent more than 25 years at the vice president level or higher, working in both startup and large company environments. He’s led global development teams through every clinical development milestone; worked closely with regulatory bodies in several different countries; overseen successful breakthrough designations and accelerated approvals; and managed complex label negotiations for initial product approvals. Schooley holds a Ph.D. in Biostatistics from the University of Michigan School of Public Health. He earned a Master of Science in Statistics and Bachelor of Science in Business Management at Brigham Young University.
With more than 20 years of experience as a financial executive, Wade Smith joined Elevar Therapeutics in January 2022 after spending the previous decade at Viatris (formerly Mylan Pharmaceuticals), a global health care company working in a broad range of therapeutic areas. Smith was Viatris’s head of U.S. institutional commercial/finance from 2017-2022, functioning as the COO and CFO for the $1 billion+ division. He developed a go-to-market strategy for more than 100 new products, overseeing launch pricing, customer contracting, managed care engagement and sales targeting in addition to portfolio selection and budgeting/forecasting. He was previously director of global accounting and financial reporting for Taggart Global USA, LLC, a multinational engineering and construction company.
Tyler Wiseman joined Elevar Therapeutics in May 2022 after serving as corporate counsel for Praxis Precision Medicines Inc. since August 2020. He played a lead role in developing Praxis’s legal infrastructure and strengthening its team, processes, policies and templates, while overseeing legal review and approval of all company contracts. Wiseman was also instrumental in managing the company’s data privacy, intellectual property, employment and litigation law.
Wiseman holds a J.D. degree from Suffolk University Law School and is admitted to the Massachusetts Bar. He also holds an MBA (magna cum laude) from Endicott College and a bachelor’s degree (magna cum laude) from Northeastern University.